Progenics: ASCO Genitourinary Cancers Symposium (Progenics) - Feb 27, 2015 - "Summary/Conclusions"; "In patients with progressive mCRPC following abi/enz, treatment with PSMA ADC resulted in CTC conversion from unfavorable to favorable status in 47% and CTC declines of ≥50% in 78% of all patients; chemo-naïve patients showed conversion in 53% and declines of ≥50% in 89%"; "Reductions of PSA ≥30% and ≥50% are seen in 30% and 14% of all patients, respectively, and 32% and 21% of chemo-naïve patients"; "PSA and CTC responses were more prominent in patients with high PSMA expression and low neuroendocrine biomarkers"; "Radiologic responses (complete and partial) and stable disease were seen in a majority of patients"; "2.3 mg/kg is generally well tolerated and appears to be better tolerated than 2.5 mg/kg; most common AE’s are neutropenia, fatigue, electrolyte imbalance, anemia and neuropathy"
P2 data • Oncology • Prostate Cancer
|